Fulgent Genetics, Inc. filings document operating results, business updates, governance matters, capital-structure activity, and clinical disclosures for a company with laboratory services and therapeutic development operations. Form 8-K reports furnish earnings releases, investor presentation updates, stock repurchase activity, and material-event disclosures tied to the company's business and pipeline.
The company's proxy materials cover board and shareholder voting matters, executive compensation, equity awards, and other governance disclosures. Clinical and regulatory filings include updates related to FID-007 in recurrent or metastatic head and neck squamous cell carcinoma, while broader disclosures address financial performance, risk, and capital allocation.
Fulgent Genetics CEO Ming Hsieh reported a Form 4 showing shares withheld for taxes on vested stock awards, not an open‑market trade. On June 1, 2026, 4,392 shares of common stock were disposed of at $18.09 per share to satisfy tax withholding obligations from restricted stock units granted on February 25, 2025.
After this tax-withholding disposition, Hsieh directly holds 893,293 common shares. He also has substantial indirect holdings through family and trust structures, including shares held by the Ming Hsieh Trust, the Dynasty Trust, a Uniform Transfers to Minor Act account, and an immediate family member residing in the same household.
Fulgent Genetics filed a Form 144 notice reporting intended resale of restricted common stock that vested on 02/25/2025. The filing lists 45,304 shares linked to equity compensation and discloses a prior sale of 1,201 shares on 05/27/2026.
The notice names Jian Xie and gives broker information for Morgan Stanley Smith Barney LLC. The filing is administrative: it reports quantities and dates related to restricted stock and a recent small disposition.
Fulgent Genetics filed an 8-K to share updated clinical data for its cancer drug candidate FID-007. The company presented preliminary Phase 2 results at the ASCO 2026 Annual Meeting in a rapid oral abstract session focused on head and neck cancer.
The open-label, randomized Phase 2 study evaluates two dosing regimens of FID-007 combined with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma whose disease progressed after PD-1–based immunotherapy. As of the April 16, 2026 data cutoff, investigators reported meaningful clinical activity and a manageable safety profile.
According to a principal investigator, the combination produced an objective response rate of 61.9%, median progression-free survival of 6.7 months, median duration of response of 7.4 months, and one-year overall survival of 63.4%. A Phase 3 study of FID-007 is planned, and the ASCO presentation slides are being made available on Fulgent’s investor relations website.
Fulgent Genetics, Inc. President and COO Jian Xie reported an open-market sale of 1,201 shares of common stock on May 27, 2026 at a weighted-average price of $17.60 per share. The shares were sold to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on February 26, 2024.
Following the sale, Xie directly holds 369,751 shares of Fulgent Genetics common stock. An additional 220,816 shares are held indirectly by The Hsieh Family Dynasty Trust, where Xie serves on the investment committee and disclaims beneficial interest except for any pecuniary interest.
Fulgent Genetics, Inc. CFO and Treasurer Paul Kim reported a routine tax-related share disposition. On May 26, 2026, 1,168 shares of common stock were withheld to cover tax obligations arising from the vesting of restricted stock units granted on February 26, 2024. After this withholding, Kim directly holds 364,632 common shares.
Fulgent Genetics, Inc. Chief Scientific Officer Hanlin Gao reported an open-market sale of common stock. On May 27, 2026, he sold 945 shares at a weighted-average price of $17.60 per share to satisfy tax withholding obligations from vested restricted stock units. After this transaction, Gao directly held 992,062 shares of Fulgent Genetics common stock, so the sale represents only a small fraction of his overall stake.
Fulgent Genetics, Inc. insider Ming Hsieh filed Amendment No. 5 to update his ownership in the company’s common stock. He beneficially owns 8,872,539 shares, representing 32.26% of the 27,493,435 shares outstanding as of May 22, 2026. The Ming Hsieh Trust beneficially owns 7,895,115 shares, or 28.72% of the class.
Since the prior amendment, Hsieh acquired additional shares solely through vesting of equity awards; on May 26, 2026, 5,496 RSU shares vested, with 2,949 shares withheld for taxes, and no cash consideration was paid. A total of 1,000,000 trust shares are pledged under a pre-paid forward arrangement and 5,760,733 trust shares secure a credit facility, so the lender may dispose of these if there is a default. Hsieh indicates he holds the stake for general investment purposes but may increase or decrease his holdings over time.
Fulgent Genetics, Inc. director and Chief Executive Officer Ming Hsieh reported a routine tax withholding event related to equity compensation. Upon vesting of restricted stock units granted on February 26, 2024, 2,949 shares of common stock were withheld at $17.67 per share to satisfy tax obligations, leaving him with 897,685 directly held shares.
He also reports substantial indirect holdings, including shares held by The Ming Hsieh Trust, the Dynasty Trust, a Uniform Transfers to Minor Act account, and an immediate family member in the same household, with individual positions such as 7,895,115 shares and 220,816 shares held via trusts.
Fulgent Genetics reported interim Phase 2 results for its cancer drug candidate FID-007 in combination with cetuximab for recurrent or metastatic head and neck squamous cell carcinoma. The data come from an open-label, randomized study presented in a full abstract at ASCO 2026.
Among 42 efficacy-evaluable patients, the combination showed an objective response rate of 60%, with median progression-free survival of 7.2 months across two dosing arms. Median duration of response was 7.4 months, and over half of responders were still responding at the data cut-off of December 20, 2025.
The safety profile was described as favorable overall, with most treatment-related side effects in grades 1–2, though grade 3–4 events such as neutropenia, anemia, leukopenia and rash occurred, and there was one grade 5 treatment-related pneumonia. Overall survival data remain immature. The abstract is available on ASCO’s site, with final presentation slides to follow on June 1, 2026.
Fulgent Genetics director Michael Nohaile reported new equity awards. He received 5,558 shares of common stock as a grant, bringing his direct holdings to 24,578 shares. He was also granted options on 8,426 shares at an exercise price of $16.19 per share, expiring on May 13, 2036.
The 5,558 restricted stock units and the 8,426 options both vest over four years. One quarter vest 12 months after May 14, 2026, and the remainder vest in equal quarterly installments over the following 36 months, contingent on continued service with the company.